financetom
Business
financetom
/
Business
/
Indian beauty retailer Nykaa posts more than three-fold profit jump on robust makeup demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indian beauty retailer Nykaa posts more than three-fold profit jump on robust makeup demand
Nov 7, 2025 3:26 AM

Nov 7 (Reuters) - Indian beauty retailer Nykaa's

quarterly profit more than trebled on Friday, boosted by steady

demand for makeup and skincare products as well as new tie-ups

with global brands.

The company, formally known as FSN E-Commerce Ventures,

posted a profit of 344.4 million rupees ($3.9 million)for the

quarter ended September 30, up from 100.4 million rupees a year

ago.

The quarterly results show Nykaa is sharpening its focus on

profitability by doubling down on its core beauty business.

That has meant scaling up strategic partnerships - including

the global rollout of Katrina Kaif's Kay Beauty, and Rihanna's

Fenty Beauty - and expanding its offline presence, enabling it

to become a full-stack beauty and lifestyle platform.

The additions have helped Nykaa cater to India's $28-billion

beauty and personal care market - which has remained resilient

despite a broader consumption slowdown.

Revenue from the beauty business rose 25% to 21.32 billion

rupees, buoyed by the inclusion of premium brands such as

Chanel, Korean skincare label Aesura, and sunscreen maker

Supergoop.

Sales for its fashion vertical, which includes apparel and

accessories from labels like Victoria's Secret and Titan's

Mia, grew 21%, lifting overall revenue by 25% to 23.56

billion rupees.

Nykaa added 19 beauty stores during the quarter, taking its

total count to 265.

Gross margins expanded to 44.9% from 43.8% a year earlier,

supported by a greater focus on premium offerings.

($1 = 87.8950 Indian rupees)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Starr Announces Acquisition of IQUW Group
Starr Announces Acquisition of IQUW Group
Oct 29, 2025
Starr set to become ninth-largest Lloyd’s agency NEW YORK & LONDON--(BUSINESS WIRE)-- Starr, a global investment and insurance organization, today announced that it has entered into a definitive agreement to acquire IQUW Group. The acquisition of IQUW Group will expand the classes of business that Starr underwrites and will position the combined company for growth across a broader range...
Airbus beats Q3 expectations but cuts A220 production target
Airbus beats Q3 expectations but cuts A220 production target
Oct 29, 2025
PARIS (Reuters) -Europe's Airbus on Wednesday reported higher than expected third-quarter profits and revenues led by commercial jetliner deliveries and robust gains in helicopters and defence. It reaffirmed its main financial and delivery targets but cut the production goal for its smallest model and now aims to assemble 12 of the Canadian-designed A220s a month in 2026, down from a...
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
Oct 29, 2025
12:34 PM EDT, 10/29/2025 (MT Newswires) -- American Tower's ( AMT ) solid Q3 results and slightly higher full-year guidance were overshadowed by a legal dispute with Echostar ( SATS ) over tower payments, but the market's reaction is overdone given the wireless infrastructure provider's minimal 2% revenue exposure to Echostar ( SATS ) and the stock's attractive valuation, UBS...
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
Oct 29, 2025
12:32 PM EDT, 10/29/2025 (MT Newswires) -- Vor Biopharma ( VOR ) said Wednesday that its partner RemeGen presented 48-week data from a phase 3 study in China showing that telitacicept delivered consistent quality-of-life improvement in patients with generalized myasthenia gravis. All patients treated with telitacicept for 48 weeks achieved an at least two-point improvement in Myasthenia Gravis Activities of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved